Browse studies

Find your next paid study

6 recruiting studies matching your filters

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatmen…

Peritoneal Malignant Mesothelioma

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05001880

Phase 2

ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatmen…

Malignant Peritoneal MesotheliomaPeritoneal MesotheliomaMesothelioma+2 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06057935

Phase 2

Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subje…

MesotheliomaMalignant Mesothelioma (MM)Early-stage Mesothelioma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05960773

Phase 1

A Phase 1/2, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

This is a Phase 1/2, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumo…

Malignant MesotheliomaMetastatic Malignant Solid TumorAdvanced Solid Tumor

Estimated

~$10 – $8,750

InSilico Medicine Hong Kong LimitedNCT06566079

Phase 1

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease: A Phase I Trial

This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer t…

Malignant Pleural EffusionMalignant MesotheliomaPleural Effusion, Malignant+1 more

Estimated

~$10 – $7,500

David Bartlett, MDNCT07192900

Phase 1

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors: A Phase I Trial (FAST TILS 2)

This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer t…

Malignant Pleural EffusionMalignant MesotheliomaPleural Effusion, Malignant+1 more

Estimated

~$10 – $7,500

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)NCT07443020